Organization | Algemeen Ziekenhuis Maria Middelares

Algemeen Ziekenhuis Maria Middelares Report issue

Academic/Hospital Phase 3 Phase 4

Founded: Ghent Belgium (1934)

Organization Overview

First Clinical Trial

2016

NCT02739399

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

Algemeen Ziekenhuis Maria Middelares | AZ Maria Middelares Gent | Pieter Dewint, MD PhD

Active Ingredients

Drugs in Phase 4 Trials (10)

adalimumab (humira) (1 trial)

dexamethasone (1 trial)

levobupivacaine (chirocaine) (1 trial)

lidocaine (xylocaine) (1 trial)

norepinephrine (levophed) (1 trial)

phenylephrine (Prefrin) (2 trials)

propofol (diprivan) (1 trial)

rocuronium (zemuron) (1 trial)

sevoflurane (ultane) (1 trial)

sugammadex (bridion) (1 trial)

Drugs in Phase 3 Trials (1)

cromoglicic acid (Intal) (1 trial)

Drugs in Other Trials (1)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Hypotension (Phase 4)

Inflammatory Bowel Diseases (Phase 4)

Nausea (Phase 4)

Pain, Postoperative (Phase 4)

Postoperative Nausea and Vomiting (Phase 4)

Sinusitis (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 10
# of Trial APIs: 12